LOVE PHARMA TO EVALUATE MINING OPPORTUNITIES

Advertisement

VANCOUVER, BC, CANADA, April 05, 2023 (GLOBE NEWSWIRE) — LOVE Pharma Inc. (“LOVE” and or “the Company”) (CSE:LUV) (FSE: G1Q0) is currently evaluating mining opportunities in the battery component and power metals space. The move comes as the company aims to build shareholder value and capitalize on the growing demand for these metals globally.

As the world continues to transition into renewable energy sources, there is a significant increase in demand for battery metals such as lithium cobalt and nickel. These metals are crucial components of batteries used in electric vehicles, smartphones, and other portable devices. Additionally, there is a growing need for power metals like copper and zinc, which are used in renewable energy infrastructure and power generation.

By evaluating mining opportunities in these spaces both domestic and internationally, Love is positing itself to take advantage of this growing demand. The company’s leadership team believe that investing in these metals now could lead to significant long-term benefits for the company, its shareholders and the carbon footprint of the planet.

Advertisement

The company is currently conducting due diligence on various mining opportunities and will update its shareholders as decisions are made in the coming weeks. Any investment or acquisition is not guaranteed and will be subject to regulatory approval. 

 

About Love Pharma Inc.

With a focus on the global sexual Health and Wellness markets, Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

For further information, please contact:

Investor Relations

Telephone: 1 (604) 343-2977

E-mail: [email protected]

www.love-pharma.com

 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates”, “may” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved.  A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID–19, including the impact of COVID–19 on the Company’s business, financial condition and results of operations, lack of investor demand for Bitcoin and/or Bitcoin futures exchange traded funds, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

CONTACT: Ivy Lu Love Pharma 604-568-0149 [email protected] 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.